Gastrointestinal Cancer: From Cellular and Molecular Mechanisms to Therapeutic Opportunities

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1070

Special Issue Editors

Special Issue Information

Dear Colleagues,

Gastrointestinal cancer includes all cancers arising in the digestive tract organs, such as esophageal and gastric cancers, hepatobiliary cancers, pancreatic cancers, and colorectal cancers. When combined together, gastrointestinal cancers account for more new cases and deaths per year than cancers occurring in any other system of the body, and their incidence continues to increase. Additionally, in most cases, these malignancies are diagnosed at an advanced stage, leading to a poor prognosis despite the availability of different therapeutic approaches (e.g., chemotherapy, immunotherapy, radiotherapy). Even in patients with potentially curative cancer, almost half of them will develop recurrent disease. Despite recent technological advances and major scientific efforts, the cellular and molecular pathways that underpin the pathogenesis and progression of these malignancies are still being uncovered. Better knowledge of these mechanisms can definitely improve our understanding of gastrointestinal cancer cell biology and offer opportunities for the design of new and more effective therapeutic strategies.

In this Special Issue, we invite scholars working on gastrointestinal cancer to submit original research papers or review articles dealing with novel mechanistic insights and details of the molecular signatures of oncogenic transformation and disease progression. We also encourage the submission of manuscripts that focus on translating basic molecular knowledge to new medical applications. Articles focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including possible clinical trials, are also welcomed.

Dr. Federica Laudisi
Dr. Carmine Stolfi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • gastric cancer
  • liver cancer
  • pancreatic cancer
  • tumor microenvironment
  • cytokines
  • epigenetic
  • checkpoint inhibitors
  • biomarkers
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1092 KiB  
Review
B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature
by Sylwia Mielcarska, Anna Kot, Agnieszka Kula, Miriam Dawidowicz, Piotr Sobków, Daria Kłaczka, Dariusz Waniczek and Elżbieta Świętochowska
Cells 2025, 14(7), 530; https://doi.org/10.3390/cells14070530 - 2 Apr 2025
Viewed by 714
Abstract
B7-H3 (CD276), a member of the B7 immune checkpoint family, plays a critical role in modulating immune responses and has emerged as a promising target in cancer therapy. It is highly expressed in various malignancies, where it promotes tumor evasion from T cell [...] Read more.
B7-H3 (CD276), a member of the B7 immune checkpoint family, plays a critical role in modulating immune responses and has emerged as a promising target in cancer therapy. It is highly expressed in various malignancies, where it promotes tumor evasion from T cell surveillance and contributes to cancer progression, metastasis, and therapeutic resistance, showing a correlation with the poor prognosis of patients. Although its receptors were not fully identified, B7-H3 signaling involves key intracellular pathways, including JAK/STAT, NF-κB, PI3K/Akt, and MAPK, driving processes crucial for supporting tumor growth such as cell proliferation, invasion, and apoptosis inhibition. Beyond immune modulation, B7-H3 influences cancer cell metabolism, angiogenesis, and epithelial-to-mesenchymal transition, further exacerbating tumor aggressiveness. The development of B7-H3-targeting therapies, including monoclonal antibodies, antibody–drug conjugates, and CAR-T cells, offers promising avenues for treatment. This review provides an up-to-date summary of the B7H3 mechanisms of action, putative receptors, and ongoing clinical trials evaluating therapies targeting B7H3, focusing on the molecule’s role in gastrointestinal tumors. Full article
Show Figures

Figure 1

Back to TopTop